<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36579544</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>03</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2075-4426</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>11</Issue><PubDate><Year>2022</Year><Month>Nov</Month><Day>02</Day></PubDate></JournalIssue><Title>Journal of personalized medicine</Title><ISOAbbreviation>J Pers Med</ISOAbbreviation></Journal><ArticleTitle>Long COVID Syndrome Presenting as Neuropsychiatric Exacerbations in Autism Spectrum Disorder: Insights for Treatment.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1815</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/jpm12111815</ELocationID><Abstract><AbstractText>COVID-19 causes not only severe respiratory symptoms, but also long-term sequelae, even if the acute-phase symptoms are minor. Neurological and neuropsychiatric symptoms are emerging as major long-term sequalae. In patients with pre-existing behavioral symptoms, such as individuals with autism spectrum disorders (ASD), the emergence of neuropsychiatric symptoms due to long COVID can be difficult to diagnose and manage. Herein, we present three ASD cases who presented with markedly worsening neuropsychiatric symptoms following COVID-19 exposure and subsequent difficulty in managing the post-COVID neuropsychiatric symptoms. Case 1 contracted SARS-CoV-2 during the early stages of the pandemic and treatment targeting COVID-19-induced immune activation was delayed. Case 2 was asymptomatic in the acute stage of a confirmed COVID-19 exposure, but still developed significant neuropsychiatric symptoms. Case 3 demonstrated a difficult course, partly due to pre-existing immune dysregulation and prior use of multiple immunomodulating agents. In cases 1 and 3 for whom serial blood samples were obtained, notable changes in the production of inflammatory and counter-regulatory cytokines by peripheral blood monocytes were observed. The presented cases illustrate the profound effects of COVID-19 on neuropsychiatric symptoms in ASD subjects and the difficulty of managing long-COVID symptoms.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jyonouchi</LastName><ForeName>Harumi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Saint Peter's University Hospital (SPUH), New Brunswick, NJ 08901, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geng</LastName><ForeName>Lee</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Saint Peter's University Hospital (SPUH), New Brunswick, NJ 08901, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rossignol</LastName><ForeName>Daniel A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Rossignol Medical Center, Aliso Viejo, CA 92656, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frye</LastName><ForeName>Richard E</ForeName><Initials>RE</Initials><Identifier Source="ORCID">0000-0003-4442-2937</Identifier><AffiliationInfo><Affiliation>Rossignol Medical Center, Phoenix, AZ 85050, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>None</GrantID><Agency>Jonty Foundation, St. Paul, MN</Agency><Country/></Grant><Grant><GrantID>None</GrantID><Agency>The Brain Foundation, Pleasanton, CA.</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>J Pers Med</MedlineTA><NlmUniqueID>101602269</NlmUniqueID><ISSNLinking>2075-4426</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ASD</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">monocyte cytokine</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>10</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>29</Day><Hour>4</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>30</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>11</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36579544</ArticleId><ArticleId IdType="pmc">PMC9695881</ArticleId><ArticleId IdType="doi">10.3390/jpm12111815</ArticleId><ArticleId IdType="pii">jpm12111815</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brussow H. COVID-19 and children: Medical impact and collateral damage. Microb. Biotechnol. 2022;15:1035&#x2013;1049. doi: 10.1111/1751-7915.14018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1751-7915.14018</ArticleId><ArticleId IdType="pmc">PMC8966019</ArticleId><ArticleId IdType="pubmed">35182108</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunsky Y., Jahoda A., Navas P., Campanella S., Havercamp S.M. The mental health and well-being of adults with intellectual disability during the COVID-19 pandemic: A narrative review. J. Policy Pract. Intellect. Disabil. 2022;19:35&#x2013;47. doi: 10.1111/jppi.12412.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jppi.12412</ArticleId><ArticleId IdType="pmc">PMC9115206</ArticleId><ArticleId IdType="pubmed">35601014</ArticleId></ArticleIdList></Reference><Reference><Citation>Siberry V.G.R., Rowe P.C. Pediatric long COVID and myalgic encephalomyelitis/chronic fatigue syndrome: Overlaps and opportunities. Pediatr. Infect. Dis. J. 2022;41:139&#x2013;141. doi: 10.1097/INF.0000000000003477.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0000000000003477</ArticleId><ArticleId IdType="pmc">PMC8919937</ArticleId><ArticleId IdType="pubmed">35121715</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano J.B., Murthy S., Marshall J.C., Relan P., Diaz J.V. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect. Dis. 2022;22:102&#x2013;107. doi: 10.1016/S1473-3099(21)00703-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00703-9</ArticleId><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmermann P., Pittet L.F., Curtis N. How common is long COVID in children and adolescents? Pediatr. Infect. Dis. J. 2021;40:482&#x2013;487. doi: 10.1097/INF.0000000000003328.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0000000000003328</ArticleId><ArticleId IdType="pmc">PMC8575095</ArticleId><ArticleId IdType="pubmed">34870392</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludvigsson J.F. Case report and systematic review suggest that children may experience similar long-term effects to adults after clinical COVID-19. Acta. Paediatr. 2021;110:914&#x2013;921. doi: 10.1111/apa.15673.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apa.15673</ArticleId><ArticleId IdType="pmc">PMC7753397</ArticleId><ArticleId IdType="pubmed">33205450</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceban F., Ling S., Lui L.M.W., Lee Y., Gill H., Teopiz K.M., Rodrigues N.B., Subramaniapillai M., Vincenzo J.D.D., Cao B., et al. Fatigue and cognitive impairment in post-COVID-19 Syndrome: A systematic review and meta-analysis. Brain Behav. Immun. 2022;101:93&#x2013;135. doi: 10.1016/j.bbi.2021.12.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2021.12.020</ArticleId><ArticleId IdType="pmc">PMC8715665</ArticleId><ArticleId IdType="pubmed">34973396</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasserie T., Hittle M., Goodman S.N. Assessment of the frequency and variety of persistent symptoms among patients with COVID-19: A systematic review. JAMA. Netw. Open. 2021;4:e2111417. doi: 10.1001/jamanetworkopen.2021.11417.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.11417</ArticleId><ArticleId IdType="pmc">PMC8155823</ArticleId><ArticleId IdType="pubmed">34037731</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson E.M., Monje M. Microglia in cancer therapy-related cognitive impairment. Trends. Neurosci. 2021;44:441&#x2013;451. doi: 10.1016/j.tins.2021.02.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2021.02.003</ArticleId><ArticleId IdType="pmc">PMC8593823</ArticleId><ArticleId IdType="pubmed">33674135</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong T.L., Weitzer D. Long COVID and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)-a systemic review and comparison of clinical presentation and symptomatology. Medicina. 2021;57:418. doi: 10.3390/medicina57050418.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medicina57050418</ArticleId><ArticleId IdType="pmc">PMC8145228</ArticleId><ArticleId IdType="pubmed">33925784</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson E.M., Monje M. Emerging mechanistic underpinnings and therapeutic targets for chemotherapy-related cognitive impairment. Curr. Opin. Oncol. 2019;31:531&#x2013;539. doi: 10.1097/CCO.0000000000000578.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCO.0000000000000578</ArticleId><ArticleId IdType="pmc">PMC7205182</ArticleId><ArticleId IdType="pubmed">31449084</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson E.M., Nagaraja S., Ocampo A., Tam L.T., Wood L.S., Pallegar P.N., Greene J.J., Geraghty A.C., Goldstein A.K., Ni L., et al. Methotrexate chemotherapy induces persistent tri-glial dysregulation that underlies chemotherapy-related cognitive impairment. Cell. 2019;176:43&#x2013;55.e13. doi: 10.1016/j.cell.2018.10.049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2018.10.049</ArticleId><ArticleId IdType="pmc">PMC6329664</ArticleId><ArticleId IdType="pubmed">30528430</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen X., Ren J., Li X., Li J., Chen S. Parents&#x2019; personality, parenting stress, and problem behaviors of children with special needs in China before and during the COVID-19 pandemic. Curr. Psychol. 2022:1&#x2013;12. doi: 10.1007/s12144-022-03869-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12144-022-03869-3</ArticleId><ArticleId IdType="pmc">PMC9580424</ArticleId><ArticleId IdType="pubmed">36277263</ArticleId></ArticleIdList></Reference><Reference><Citation>Pol&#xf3;nyiov&#xe1; K., Ra&#x161;kov&#xe1; B., Ostatn&#xed;kov&#xe1; D. Changes in mental health during three waves of the COVID-19 pandemic in Slovakia: Neurotypical children versus children with autism spectrum disorder and their parents. Int. J. Environ. Res. Public Health. 2022;19:11849. doi: 10.3390/ijerph191911849.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph191911849</ArticleId><ArticleId IdType="pmc">PMC9565628</ArticleId><ArticleId IdType="pubmed">36231151</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen N.E., Lord C., Volkmar F.R. The diagnosis of autism: From Kanner to DSM-III to DSM-5 and beyond. J. Autism Dev. Disord. 2021;51:4253&#x2013;4270. doi: 10.1007/s10803-021-04904-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10803-021-04904-1</ArticleId><ArticleId IdType="pmc">PMC8531066</ArticleId><ArticleId IdType="pubmed">33624215</ArticleId></ArticleIdList></Reference><Reference><Citation>Jyonouchi H., Geng L. Associations between monocyte and T cell cytokine profiles in autism spectrum disorders: Effects of dysregulated innate immune responses on adaptive responses to recall antigens in a subset of ASD children. Int. J. Mol. Sci. 2019;20:4731. doi: 10.3390/ijms20194731.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20194731</ArticleId><ArticleId IdType="pmc">PMC6801811</ArticleId><ArticleId IdType="pubmed">31554204</ArticleId></ArticleIdList></Reference><Reference><Citation>Eom T.H., Lee H.S., Jang P.S., Kim Y.H. Valproate-induced panhypogammaglobulinemia. Neurol Sci. 2013;34:1003&#x2013;1004. doi: 10.1007/s10072-012-1153-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-012-1153-3</ArticleId><ArticleId IdType="pubmed">22797722</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein H.E., Hauptman J.S. The putative role of mTOR inhibitors in non-tuberous sclerosis complex-related epilepsy. Front Neurol. 2021;12:639319. doi: 10.3389/fneur.2021.639319.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2021.639319</ArticleId><ArticleId IdType="pmc">PMC7907183</ArticleId><ArticleId IdType="pubmed">33643212</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinman G., Mankuta D. Antepartum COVID-19 and postpartum autism. Austin J. Clin. Neurol. 2021;8:1149.</Citation></Reference><Reference><Citation>Premraj L., Kannapadi N.V., Briggs J., Seal S.M., Battaglini D., Fanning J., Suen J., Robba C., Fraser J., Cho S.M. Mid and long-term neurological and neuropsychiatric manifestations of post-COVID-19 syndrome: A meta-analysis. J. Neurol Sci. 2022;434:120162. doi: 10.1016/j.jns.2022.120162.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2022.120162</ArticleId><ArticleId IdType="pmc">PMC8798975</ArticleId><ArticleId IdType="pubmed">35121209</ArticleId></ArticleIdList></Reference><Reference><Citation>Savino R., Carotenuto M., Polito A.N., Noia S.D., Albenzio M., Scarinci A., Ambrosi A., Sessa F., Tartaglia N., Messina G. Analyzing the potential biological determinants of autism spectrum disorder: From neuroinflammation to the kynurenine pathway. Brain. Sci. 2020;10:631. doi: 10.3390/brainsci10090631.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/brainsci10090631</ArticleId><ArticleId IdType="pmc">PMC7563403</ArticleId><ArticleId IdType="pubmed">32932826</ArticleId></ArticleIdList></Reference><Reference><Citation>Komada M., Nishimura Y. Epigenetics and neuroinflammation associated with neurodevelopmental disorders: A microglial perspective. Front Cell Dev. Biol. 2022;10:852752. doi: 10.3389/fcell.2022.852752.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2022.852752</ArticleId><ArticleId IdType="pmc">PMC9133693</ArticleId><ArticleId IdType="pubmed">35646933</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-Castaneda A., Lu P., Geraghty A.C., Song E., Lee M.H., Wood J., O&#x2019;Dea M.R., Dutton S., Shamardani K., Nwangwu K., et al. Mild respiratory COVID can cause multi-lineage neural cell and myelin dysregulation. Cell. 2022;185:2452&#x2013;2468.e16. doi: 10.1016/j.cell.2022.06.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.06.008</ArticleId><ArticleId IdType="pmc">PMC9189143</ArticleId><ArticleId IdType="pubmed">35768006</ArticleId></ArticleIdList></Reference><Reference><Citation>Sefik E., Qu R., Junqueira C., Kaffe E., Mirza H., Zhao J., Brewer J.R., Han A., Steach H.R., Israelow B., et al. Inflammasome activation in infected macrophages drives COVID-19 pathology. Nature. 2022;606:585&#x2013;593. doi: 10.1038/s41586-022-04802-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04802-1</ArticleId><ArticleId IdType="pmc">PMC9288243</ArticleId><ArticleId IdType="pubmed">35483404</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan F.J., Hope C.M., Masavuli M.G., Lynn M.A., Mekonnen Z.A., Yeow A.E.L., Garcia-Valtanen P., Al-Delfi Z., Gummow J., Ferguson C., et al. Long-term perturbation of the peripheral immune system months after SARS-CoV-2 infection. BMC Med. 2022;20:26. doi: 10.1186/s12916-021-02228-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-021-02228-6</ArticleId><ArticleId IdType="pmc">PMC8758383</ArticleId><ArticleId IdType="pubmed">35027067</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehandru S., Merad M. Pathological sequelae of long-haul COVID. Nature Immunology. 2022;23:194&#x2013;202. doi: 10.1038/s41590-021-01104-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01104-y</ArticleId><ArticleId IdType="pmc">PMC9127978</ArticleId><ArticleId IdType="pubmed">35105985</ArticleId></ArticleIdList></Reference><Reference><Citation>Toro-Huamanchumo C.J., Benites-Meza J.K., Mamani-Garcia C.S., Bustamante-Paytan D., Garcia-Ramos A.E., Diaz-V&#xe9;lez C., Baroza J.J. Efficacy of colchicine in the treatment of COVID-19 patients: A systematic review and meta-analysis. J. Clin. Med. 2022;11:2615. doi: 10.3390/jcm11092615.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11092615</ArticleId><ArticleId IdType="pmc">PMC9105993</ArticleId><ArticleId IdType="pubmed">35566737</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonaventura A., Vecchi&#xe9; A., Dagna L., Tangianu F., Abbate A., Dentali F. Colchicine for COVID-19: Targeting NLRP3 inflammasome to blunt hyperinflammation. Inflamm. Res. 2022;71:293&#x2013;307. doi: 10.1007/s00011-022-01540-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00011-022-01540-y</ArticleId><ArticleId IdType="pmc">PMC8811745</ArticleId><ArticleId IdType="pubmed">35113170</ArticleId></ArticleIdList></Reference><Reference><Citation>Mansouri N., Marjani M., Tabarsi P., von Garnier C., Mansouri D. Successful treatment of Covid-19 associated cytokine release syndrome with colchicine. A case report and review of literature. Immunol. Investig. 2021;50:884&#x2013;890. doi: 10.1080/08820139.2020.1789655.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08820139.2020.1789655</ArticleId><ArticleId IdType="pmc">PMC7441796</ArticleId><ArticleId IdType="pubmed">32633162</ArticleId></ArticleIdList></Reference><Reference><Citation>Naik R.R., Shakya A.K., Aladwan S.M., Eltanani M. Kinase inhibitors as potential therapeutic agents in the treatment of COVID-19. Front. Pharmacol. 2022;13:806568. doi: 10.3389/fphar.2022.806568.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2022.806568</ArticleId><ArticleId IdType="pmc">PMC9014181</ArticleId><ArticleId IdType="pubmed">35444538</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatterjee B., Thakur S.S. Remdesivir and its combination with repurposed drugs as COVID-19 therapeutics. Front. Immunol. 2022;13:830990. doi: 10.3389/fimmu.2022.830990.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.830990</ArticleId><ArticleId IdType="pmc">PMC9134007</ArticleId><ArticleId IdType="pubmed">35634324</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>